373 related articles for article (PubMed ID: 36045675)
1. The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies.
Ileiwat ZE; Tabish TA; Zinovkin DA; Yuzugulen J; Arghiani N; Pranjol MZI
Front Immunol; 2022; 13():976677. PubMed ID: 36045675
[TBL] [Abstract][Full Text] [Related]
2. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation.
Liang Q; Zhou L; Li Y; Liu J; Liu Y
J Drug Target; 2022 Feb; 30(2):119-130. PubMed ID: 33960252
[TBL] [Abstract][Full Text] [Related]
3. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
4. κ Opioid receptor ligands regulate angiogenesis in development and in tumours.
Yamamizu K; Hamada Y; Narita M
Br J Pharmacol; 2015 Jan; 172(2):268-76. PubMed ID: 24417697
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor vascularization: promising strategies for vascular normalization.
Zheng R; Li F; Li F; Gong A
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
7. Vascular normalisation as the stepping stone into tumour microenvironment transformation.
Magnussen AL; Mills IG
Br J Cancer; 2021 Aug; 125(3):324-336. PubMed ID: 33828258
[TBL] [Abstract][Full Text] [Related]
8. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
9. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.
Ansari MJ; Bokov D; Markov A; Jalil AT; Shalaby MN; Suksatan W; Chupradit S; Al-Ghamdi HS; Shomali N; Zamani A; Mohammadi A; Dadashpour M
Cell Commun Signal; 2022 Apr; 20(1):49. PubMed ID: 35392964
[TBL] [Abstract][Full Text] [Related]
10. Smart Nanotherapeutic Targeting of Tumor Vasculature.
Li Z; Di C; Li S; Yang X; Nie G
Acc Chem Res; 2019 Sep; 52(9):2703-2712. PubMed ID: 31433171
[TBL] [Abstract][Full Text] [Related]
11. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
Mander KA; Finnie JW
Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6: an angiogenic target in solid tumours.
Middleton K; Jones J; Lwin Z; Coward JI
Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
[TBL] [Abstract][Full Text] [Related]
13. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.
Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y
Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018
[TBL] [Abstract][Full Text] [Related]
14. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
15. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and angiogenesis inhibitors in cancer.
Giavazzi R; Taraboletti G
Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenesis in cancer therapeutics: the magic bullet.
Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
[TBL] [Abstract][Full Text] [Related]
18. Tumour-Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis.
Lopes-Bastos BM; Jiang WG; Cai J
Anticancer Res; 2016 Mar; 36(3):1119-26. PubMed ID: 26977007
[TBL] [Abstract][Full Text] [Related]
19. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
20. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
Missiaen R; Mazzone M; Bergers G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
